Cogent Biosciences, Inc. · NASDAQ:COGT
Cogent Biosciences — Unum Therapeutics — Investor Presentation (January 2020)
28 slides from Cogent Biosciences's investor presentation, Jan 13, 2020
Slide 1: Corporate presentation January 2020
Corporate presentation JANUARY 2020 Exhibit 99.1
Slide 2: Forward-Looking Statements and Risk Factors
Forward-Looking Statements and Risk Factors This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materiall
Slide 3: Focused on developing cures for solid tumors through cell therapy
Cancers are notorious for developing ways to suppress, evade and attack the body’s natural defense systems, rendering many therapies ineffective. Unum Therapeutics is focused on developing cures for patients with solid tumors through cell therapy approaches designed to improve the body’s immune resp
Slide 4: Experienced Leadership Team
Experienced Leadership Team Unum’s leadership possesses biotech and large pharma drug development experience and deep scientific expertise in cancer immunotherapy GEOFFREY HODGE Chief Technical Officer CHUCK WILSON, Ph.D. President and CEO ERIN SCHELLHAMMER VP, People SETH ETTENBERG, Ph.D. Chief Sci
Slide 5: Novel Technologies Designed to Improve T Cell Functionality and Targeting
Novel Technologies Designed to Improve T Cell Functionality and Targeting Bolt-On Chimeric Receptor (BOXR): Overcoming Tumor Immunosuppression Antibody-Coupled T Cell Receptor (ACTR): Selective Tumor Targeting
Slide 6: BOXR Technology: Overcoming the Solid Tumor Microenvironment
BOXR Technology: Overcoming the Solid Tumor Microenvironment (TME) BOXR program candidates are designed to overcome the suppressive effects of the TME, including: Competition for metabolites Exhaustion due to chronic stimulation Resistance to immunosuppressive cell types Novel bolt-on transgenes cou
Slide 7: ACTR Technology: Next Generation Cell Therapy
ACTR Technology: Next Generation Cell Therapy Tumor-specific antibodies form a bridge between tumor cell antigens and ACTR receptors to drive T cell attack ACTR uses components from naturally-occurring immune receptors ACTR T cells drive selective tumor cell attack while sparing normal tissue
Slide 8: A Focused Plan to Treat More Cancers
A Focused Plan to Treat More Cancers BOXR (CAR) ROR1+ cancers (ovarian, breast, others) DISCOVERY BOXR (ACTR) Undisclosed BOXR (ACTR) Undisclosed PHASE 1 ACTR707+ trastuzumab HER2+ cancers (breast, gastric, others) ACTR707+ rituximab CD20+ B cell NHL PRE-CLINICAL BOXR1030 GPC3+ cancers (liver, lung,
Slide 9: UNUM
UNUM 9
Slide 10: BOXR1030: GOT2 Transgene + GPC3 CAR
BOXR1030: GOT2 Transgene + GPC3 CAR Glutamic-oxaloacetic transaminase 2 (GOT2) is a critical mitochondrial enzyme for cell survival, proliferation and differentiation Glypican-3 (GPC3) is highly expressed in several solid tumor types; not in normal tissues BOXR1030 T cells have improved metabolism a
Slide 11: BOXR1030: Targeting GPC3+ Cancers
BOXR1030: Targeting GPC3+ Cancers GPC3 a validated target; potential to improve upon current clinical programs GPC3 is highly expressed in several solid tumor types, not in normal tissues INDICATION %GPC3+ HCC 75 Lung SqCC 55 Lung SCLC 20 Lung Adeno 12 Cervical 20 Gastric 20 Ovarian 12 In clinical s
Slide 12: GOT2: A Regulator of Cellular Metabolism
GOT2: A Regulator of Cellular Metabolism GOT2 is a critical enzyme for cell survival, proliferation and differentiation BETTER T CELL FUNCTION IMPROVED METABOLISM POTENT ANTI-TUMOR ACTIVITY GOT2 BOLT-ON
Slide 13: BOXR1030: Improving T Cell Metabolism in the TME
BOXR1030: Improving T Cell Metabolism in the TME Metabolic profiling reveals enriched metabolites in BOXR1030 consistent with GOT2 enzymatic activity GSH Alanine GSSG Aspartate BOXR1030’s unique transcriptional profile indicates improved metabolism and better stress response GPC3 CAR BOXR1030 Pathwa
Slide 14: BOXR1030: Overcomes T Cell Exhaustion and Improves Function
BOXR1030: Overcomes T Cell Exhaustion and Improves Function in Preclinical Studies BOXR T cells in the tumor display less exhaustion BOXR T cells in the tumor retain function BOXR1030 activation only occurs at tumor site TUMOR Spleen CD69 (gMFI) 800 600 400 200 0 BOXR1030 GPC3 CAR 60 40 20 0 PD1+Tim
Slide 15: BOXR1030: Reduced Tumor Burden in Mouse Xenografts
BOXR1030: Reduced Tumor Burden in Mouse Xenografts Chronic Stimulation (Hep3B) Low Glucose (JHH7) PD-L1 High and Low Glucose (NCI-H446) Control GPC3 CAR T BOXR1030 TME Characteristics (Cell Line) Day Tumor Volume (mm3) Addition of the GOT2 transgene resulted in complete tumor regressions with GPC3-t
Slide 16: BOXR Platform: Potential for Broad Pipeline Expansion
Unum’s Bolt-On genes can yield multiple novel candidates from: Different Targeting Receptors CAR ACTR TCR Different Immune Cells ⍺β T cells γδ T cells NK cells Different Cell Sources Circulating patient cells (autologous) Donor-derived cells (allogeneic) Tumor infiltrates (e.g., TILs) BOXR Platform:
Slide 17: BOXR1030/Platform Next Steps
BOXR 1030/Platform Next Steps BOXR1030 GMP viral and T cell process development in progress Preclinical characterization of activity and preliminary safety studies conducted Clinical plan/protocol in preparation On track for IND filing in late 2020 BOXR PLATFORM Targeting ROR1 to address unmet need
Slide 18: UNUM
69 UNUM
Slide 19: ACTR: Antibody-Coupled T Cell Receptor
ACTR: Antibody-Coupled T Cell Receptor Autologous engineered T cell therapy designed to combine the cell-killing ability of T cells and the tumor-targeting ability of antibodies to exert potent antitumor activity Structure NK Fc receptor ectodomain linked to standard CAR signaling components Mechani
Slide 20: Proof Of Concept: Anti-tumor Activity R/R NHL
Proof Of Concept: Anti-tumor Activity R/R NHL Treatment with ACTR707 and rituximab generated robust clinical responses without T cell mediated toxicities of CRS or severe neurotoxicity Of 8 CRs, 6 were ongoing at last scan (4 >6 mos and 2 <6 mos); 2 progressed prior to the 6 month timepoint Potent a
Slide 21: R/R NHL: Safety Data for Cohorts 1–4
R/R NHL: Safety Data for Cohorts 1–4 ACTR707 in combination with rituximab was well-tolerated in initial cohorts of ATTCK-20-03 No dose-limiting toxicities (DLTs), no cytokine-release syndrome (CRS) or severe neurotoxicity events reported ACTR707 Preliminary Phase 1 trial safety results in r/r NHL (
Slide 22: ACTR707: Optimized for Solid Tumors
ACTR707: Optimized for Solid Tumors ACTR707 was discovered by screening 100+ ACTR constructs for improved potential in solid tumors Selective for on-tumor attack, sparing normal tissues with low levels of antigen expression tumor cell lines (HER2 high) normal tissue cells (HER2 low) ACTR + trastuzum
Slide 23: Address 3rd Line + Patients
ENTRY: Address 3rd Line + Patients Current standard: mPFS of 3-6 months1 ACTR target: PFS measured in years, not months CURATIVE POTENTIAL: Durable complete responses Current standard: CR rate 0-6%2 ACTR target: Durable CRs are a reality EXPANSION: Move to earlier lines Current standard: CR rate <10
Slide 24: ATTCK-34-01: Phase 1 Trial of ACTR707 in HER2+ Tumors
ATTCK-34-01: Phase 1 Trial of ACTR707 in HER2+ Tumors ELIGIBILITY Advanced HER2 (3+) solid tumor malignancy, adequate prior therapy including HER2 directed therapy if available OBJECTIVES Demonstrate safety, tolerability, clinical response and determine recommended Phase 2 dose STATUS Completed enro
Slide 25: ATTCK-34-01: Planned Efficacy/Biomarker Readouts
ATTCK-34-01: Planned Efficacy/Biomarker Readouts EFFICACY MEASURES Overall response rate per iRECIST, duration of response, progression-free survival, overall survival BIOMARKERS Persistence of ACTR by flow cytometry and qPCR ACTR phenotype and function Inflammatory markers and cytokines/chemokines
Slide 26: Value-Creating Milestones
Value-Creating Milestones PROGRAM INDICATION EVENT TIMING ACTR707/087 r/r NHL Safety/efficacy data from Phase 1 trials (ATTCK-20-2, ATTCK-20-03) ✓ ACTR707 HER2+ tumors Preliminary safety data from Cohort 1 from Phase 1 trial (ATTCK-34-01) 1Q 2020 ACTR707 r/r NHL Cohorts 5 & 6 data from Phase 1 trial
Slide 27: A Focused Plan to Treat More Cancers
A Focused Plan to Treat More Cancers BOXR (CAR) ROR1+ cancers (ovarian, breast, others) DISCOVERY BOXR (ACTR) Undisclosed BOXR (ACTR) Undisclosed PHASE 1 ACTR707+ trastuzumab HER2+ cancers (breast, gastric, others) ACTR707+ rituximab CD20+ B cell NHL PRE-CLINICAL BOXR1030 GPC3+ cancers (liver, lung,
Slide 28: Thank you
Thank you unumrx.com Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140 USA
Unum Therapeutics — Investor Presentation (January 2020) on 6ix